Navigation Links
Coronary calcium distribution tied to heart attack risk
Date:5/26/2008

OAK BROOK, Ill. A new calcium scoring method may better predict a persons risk of heart attack, according to a new multicenter study published in the June issue of the journal Radiology. Calcium coverage scoring takes into account not only the amount of calcified plaque build-up in the coronary arteries, but also its distribution.

Now we know that the location of the calcium in the arteries is particularly important in estimating a patients potential risk, said the studys lead author Elizabeth Brown, Sc.D., research assistant professor in the Department of Biostatistics at the University of Washington in Seattle.

Heart disease is the leading cause of death in the U.S. Each year, 700,000 Americans die of heart disease, according to the Centers for Disease Control and Prevention. The most common form of heart disease in the U.S. is coronary artery disease, which is caused by a build-up of calcific plaque in the coronary arteries leading to the heart. The current standard of coronary calcium measurement gauges only the amount of calcium present in the arteries, not its spatial distribution.

Currently, physicians only see the result in terms of an overall score designed to measure the amount of calcified plaque, Dr. Brown said. This new approach will provide physicians with a measure of the proportion of the arteries affected.

The Multi-Ethnic Study of Atherosclerosis (MESA) began in July 2000. The prospective study included 6,814 men and women between the ages of 45 and 84. The researchers compared CT image data for 3,252 participants with calcific plaque to data collected from 3,416 patients without calcific plaque. (Due to lack of sufficient CT image data, 146 additional MESA participants were excluded from this analysis.) A calcium coverage score was developed to estimate the percentage of coronary arteries affected by plaque.

The patients were then followed up for a median period of 41 months to determine if there
'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. When statins arent enough: New trial drug points to better management of coronary heart disease
2. MAQUET Cardiovascular Launches HEARTSTRING III Proximal Seal System for Coronary Artery Bypass Graft Surgery
3. Extremely low dose CT coronary angiography shows promise in assessing cardiac function
4. Clopidogrel reloading worthwhile in acute coronary syndromes
5. New Drug Shows Promise in Use With Coronary Stents
6. Calcium Scans Help Predict Coronary Risk
7. Acute Coronary Events Drop After Italys Public Smoking Ban
8. Triglycerides Linked to Coronary Disease Risk
9. Acute coronary events decreased after public smoking ban in Italy
10. UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets
11. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation 2Health News:Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation 3Health News:'That's My Hope' Audio Edition Released 2Health News:'That's My Hope' Audio Edition Released 3Health News:Saint Francis Medical Center Physician Services Implements MED3OOO RCM and ASP Services 2Health News:Saint Francis Medical Center Physician Services Implements MED3OOO RCM and ASP Services 3Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 2Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 3Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 4Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 5Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 6Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 7Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 8Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 9Health News:AND Calls on DoD to Open All Military Units to Women, Grant Parental Leave to Service Members 2Health News:Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference 2Health News:Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference 3
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2Fresh Blood Boosts Survival in Trauma Patients 58799 1Fresh Blood Boosts Survival in Trauma Patients 58799 2Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 1Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 2Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 3Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 4Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 5Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 1Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 2Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 3Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 4Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 5